What is the latest on the masitinib prostate cancer trial, and how could it change treatment for metastatic castrate-resistant prostate cancer (mCRPC)?
The masitinib prostate cancer trial recently received simultaneous authorizations from both ...
When you partner with Syenza, it’s like a Nuclear Fusion.
Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in
health policy, health economics, systems analysis, public finance, business, and project management.
You’ll also feel our high-impact global and local perspectives with cultural intelligence.